Winette van der Graaf, President of the EORTC and Professor of Medical Oncology at The Netherlands Cancer Institute, shared a post on LinkedIn:
“Last year the The Cancer Drug Development Forum (CDDF) held a workshop on Rare Cancers to which many stakeholders (patients, clinicians, regulators, investigators from the biomedical field, quality of life researchers, pharma, clinical trial organizations) contributed. It shows how challenging the road to precision oncology is, but also where potential solutions can be found, where and how some are in place, and where others still need a lot of support and push.”
Title: Overcoming the barriers to treatment of rare cancer patients in the era of precision oncology: A call to action
Authors: Winette T.A. van der Graaf, Nina S. Heiss, Carolyn L. Hynes, Simone P. Keller, Ariane Weinman, Jean-Yves Blay, Pedro Franco, Rachel H. Giles, Denis Lacombe, Philipp Schlatter, David M. Thomas, Sahar Barjesteh van Waalwijk van Doorn-Khosrovan, Max Williamson, Ruth Plummer
Read the Full Article.
